Eli Lilly Stock: Why the Weight-Loss Boom Is Just Beginning

Join Ross’s Patreon Community for exclusive content and LIVE events https://www.patreon.com/cw/TheRealRossMandell?utm_campaign=creatorshare_creator Is Eli Lilly stock still in the early stages of the weight-loss boom? In this episode of Going Public with Ross Mandell, Ross breaks down his bullish outlook on LLY stock and explains why Mounjaro and Zepbound could be just the beginning. Explore how diabetes treatments, obesity drugs, and the growing GLP-1 market fit into his investment thesis. The discussion covers oral weight-loss treatments such as orforglipron, retatrutide’s clinical development, and Lilly’s plans to expand manufacturing and reach more patients worldwide. Ross examines the company’s earnings, revenue growth, and drug pipeline, explaining why he sees an opportunity extending beyond today’s blockbuster injections. Ross also addresses Eli Lilly’s stock pullback, valuation, competition from Novo Nordisk and other drugmakers, and the execution risks investors should watch. Learn which developments he’s tracking—from clinical trial results and international expansion to production capacity and financial guidance—and why a strong business still needs to justify its stock price. Subscribe to Going Public for more stock market analysis, healthcare stocks, and emerging investment themes. About Ross Mandell: Ross Mandell is a former Wall Street professional, entrepreneur, author, and capital formation expert. On Going Public with Ross Mandell, Ross interviews athletes, entrepreneurs, investors, doctors, creators, and high performers about success, failure, reinvention, money, health, business, and what it takes to rebuild after adversity. This content is for informational and educational purposes only and does not constitute financial or investment advice. 🔗 Links & Resources 📌 Book A Call With Ross https://buy.stripe.com/9B64gydlh4dJfhXecP5Vu08 📲 Follow Ross Mandell on Instagram https://www.instagram.com/rossmandell/ ⏱️ Chapters 00:00 Eli Lilly Stock: The Next Phase of the Weight-Loss Boom 01:13 Eli Lilly’s History: From Insulin to Obesity Drugs 02:16 Mounjaro and Zepbound: Eli Lilly’s Revenue Growth 03:21 Orforglipron: The Oral Weight-Loss Pill Opportunity 05:20 Eli Lilly’s Manufacturing Expansion 06:12 Retatrutide Clinical Trials: The Triple-Action Obesity Drug 07:43 GLP-1 Research: New Data and Combination Treatments 08:22 Eli Lilly’s Drug Pipeline Beyond Weight Loss 09:07 LLY Stock Pullback and Revenue Guidance 10:16 Eli Lilly Stock Valuation and Novo Nordisk Competition 11:30 Why Ross Mandell Is Bullish on Eli Lilly Stock 13:18 Eli Lilly Stock: Key Catalysts and Risks to Watch 14:07 Why the Weight-Loss Boom Could Be Just Beginning Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.